Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2020 and Recent Developments
September 01, 2020 16:05 ET | Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $25.4 Million -- -- Signed Three New Customers and Project Expansion Orders with Current Customers for $20 Million -- -- Backlog of $60 Million at Quarter-End --...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
August 31, 2020 16:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody
August 26, 2020 08:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2021 After Market Close on September 1, 2020
August 25, 2020 16:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2020 and Recent Developments
June 30, 2020 16:05 ET | Avid Bioservices, Inc
-- Appointed Nicholas Green as President and Chief Executive Officer -- -- Recorded Fourth Quarter Revenue of $12.6 Million and Annual Revenue of $59.7 Million -- -- Signed $23 Million in Business...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2020 After Market Close on June 30, 2020
June 23, 2020 16:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Receives Five 2020 CMO Leadership Awards
March 26, 2020 08:05 ET | Avid Bioservices, Inc
Company Honored for Capabilities, Expertise, Reliability, Compatibility, and Service in the Contract Development and Manufacturing Industry Named 2020 CMO Leadership Award Champion in Categories of...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2020 and Recent Developments
March 10, 2020 16:05 ET | Avid Bioservices, Inc
-- Recorded Third Quarter Revenue of $13.6 Million -- -- Signed New Customer and Project Expansion Orders with Current Customers for $20 Million  -- -- Adjusting Fiscal 2020 Projected Revenue to $55...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
March 04, 2020 16:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2020 After Market Close on March 10, 2020
March 03, 2020 16:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...